Single-dose local administration of teriparatide with a octacalcium phosphate collagen composite enhances bone regeneration in a rodent critical-sized calvarial defect.

Kajii F, Iwai A, Tanaka H, Matsui K, Kawai T, Kamakura S

Journal of biomedical materials research. Part B, Applied biomaterials18 Sept 2017Cited by 19 (Europe PMC)

PMID28922546PMCIDPMC6032915DOI10.1002/jbm.b.33993PepBankPUB-28922546

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rodents with calvarial defects, adding teriparatide to OCP/Col increased radiopaque coverage compared with OCP/Col alone.
In plain wordsIn rodents with skull defects, teriparatide with OCP/Col increased radiopaque coverage compared with OCP/Col alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadiopaque defect coverage
Study
rodentn: not reported in source
Critical-sized calvarial defect
Comparator
OCP/Col alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · local implantation · 12 weeksAs given in this study (rodent).
Source sentences
Summary
Radiographic examinations indicated that radiopaque figures in defects treated with OCP/Col with TPTD (OCP/Col/TPTDd) occupied a wider range than those treated with OCP/Col.
2 context sentences(design, population, supporting numbers)
Summary · context
After the creation of a rodent critical-sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 µg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect.
Summary · context
Six defects in each group were fixed 12 weeks after implantation.
Report a problemFND-2892254601
02AnimalAnimal study (in vivo)Efficacy outcome
In rodent calvarial defects, adding teriparatide at the higher dose increased new bone percentage compared with OCP/Col alone.
In plain wordsIn rodents with skull defects, higher-dose teriparatide with OCP/Col produced more new bone than OCP/Col alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNew bone percentage with higher dose
Study
rodentn: not reported in source
Critical-sized calvarial defect
Comparator
OCP/Col alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 µg single dose · local implantation · 12 weeksAs given in this study (rodent).
Measurements
New bone
53.6%
OCP/Col/TPTDd 1.0
New bone
40.1%
OCP/Col
Source sentences
Summary
A histomorphometrical examination indicated that the percentage of newly formed bone was significantly higher in the defects of OCP/Col/TPTDd 1.0 (53.6 ± 4.3%) and OCP/Col/TPTDd 0.1 (52.2 ± 7.4%) than in those of OCP/Col (40.1 ± 8.4%), whereas no significant differences were observed between OCP/Col…
2 context sentences(design, population, supporting numbers)
Summary · context
After the creation of a rodent critical-sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 µg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect.
Summary · context
Six defects in each group were fixed 12 weeks after implantation.
Report a problemFND-2892254603
03AnimalAnimal study (in vivo)Efficacy outcome
In rodent calvarial defects, adding teriparatide at the lower dose increased new bone percentage compared with OCP/Col alone.
In plain wordsIn rodents with skull defects, lower-dose teriparatide with OCP/Col produced more new bone than OCP/Col alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNew bone percentage with lower dose
Study
rodentn: not reported in source
Critical-sized calvarial defect
Comparator
OCP/Col alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 µg single dose · local implantation · 12 weeksAs given in this study (rodent).
Measurements
New bone
52.2%
OCP/Col/TPTDd 0.1
New bone
40.1%
OCP/Col
Source sentences
Summary
A histomorphometrical examination indicated that the percentage of newly formed bone was significantly higher in the defects of OCP/Col/TPTDd 1.0 (53.6 ± 4.3%) and OCP/Col/TPTDd 0.1 (52.2 ± 7.4%) than in those of OCP/Col (40.1 ± 8.4%), whereas no significant differences were observed between OCP/Col…
2 context sentences(design, population, supporting numbers)
Summary · context
After the creation of a rodent critical-sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 µg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect.
Summary · context
Six defects in each group were fixed 12 weeks after implantation.
Report a problemFND-2892254604
04AnimalAnimal study (in vivo)Efficacy outcome
In rodent calvarial defects, new bone percentage did not differ significantly between teriparatide doses with OCP/Col.
In plain wordsIn rodents with skull defects, new bone percentage did not differ significantly between teriparatide doses with OCP/Col.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNew bone percentage between doses
Study
rodentn: not reported in source
Critical-sized calvarial defect
Comparator
OCP/Col with teriparatide 0.1 µg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 µg single dose · local implantation · 12 weeksAs given in this study (rodent).
Source sentences
Summary
whereas no significant differences were observed between OCP/Col/TPTDd1.0 and OCP/Col/TPTDd0.1.
2 context sentences(design, population, supporting numbers)
Summary · context
After the creation of a rodent critical-sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 µg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect.
Summary · context
Six defects in each group were fixed 12 weeks after implantation.
Report a problemFND-2892254605

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rodent calvarial defects treated with OCP/Col and teriparatide, newly formed bone filled most of the defect.
In plain wordsIn rodents, new bone filled most of the skull defect treated with OCP/Col and teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedHistological new bone filling
Study
rodentn: not reported in source
Critical-sized calvarial defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Histological results demonstrated that most of the defect in OCP/Col/TPTDd was filled with newly formed bone.
2 context sentences(design, population, supporting numbers)
Summary · context
After the creation of a rodent critical-sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 µg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect.
Summary · context
Six defects in each group were fixed 12 weeks after implantation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2892254602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.